64
Participants
Start Date
December 12, 2007
Primary Completion Date
February 26, 2010
Study Completion Date
October 30, 2012
AG-013736
"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
National Cancer Center East Hospital, Kashiwa
Hokkaido University Hospital, Sapporo
Tsukuba University Hospital, Tsukuba
Iwate Medical University, Morioka
Kochi Medical School Hospital, Nankoku-shi
Kinki University Hospital, Sayama
Hamamatsu University School of Medicine University Hospital, Hamamatsu
Shizuoka Cancer Center, Sunto-gun
Tokyo Women's Medical University Medical Center East, Arakawa-ku
National Cancer Center, Chuo-ku
Nihon University Itabashi Hospital, Itabashi-ku
Akita University Hospital, Akita
National Kyushu Cancer Center, Fukuoka
Kyushu University Hospital, Department of Urology, Fukuoka
University Hospital, Kyoto Prefectural University of Medicine, Kyoto
Osaka University Hospital, Osaka
Tokushima University Hospotal, Tokushima
Yamagata University Hospital, Yamagata
Lead Sponsor
Pfizer
INDUSTRY